| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 3,535,470 | 3,615,670 | 3,501,270 | 3,701,580 | 3,435,150 |
| Sales Growth | -2.22% | +3.27% | -5.41% | +7.76% | -3.02% |
| Net Income | 296,010 | 630,790 | 382,300 | 536,410 | -3,730 |
| Net Income Growth | -53.07% | +65.00% | -28.73% | +14,480.96% | -100.81% |
Haleon Plc (HLN)
10.08 +0.03 (+0.30%) 12:35 ET [NYSE]
10.08 x 11718 10.09 x 3900
Realtime by (Cboe BZX)
10.08 x 11718 10.09 x 3900
Realtime 10.06 +0.01 (+0.10%) 09:22 ET
for Thu, Mar 27th, 2025
Haleon plc engages in the research and development, manufacture and sale of various consumer healthcare products principally in North America, Europe, the Middle East, Africa, Latin America and the Asia Pacific. It provides therapeutic oral health, pain relief, respiratory health, digestive health and other products, as well as vitamins, minerals and supplements. Haleon plc is based in Brentford, the United Kingdom.
Fiscal Year End Date: 12/31